mRNA-3927

Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
BioSpace
Thu, 05/4/23 - 09:20 am
Moderna Therapeutics
vaccines
mRNA-3927
propionic acidemia
FDA grants fast track status to Moderna’s mRNA therapeutic to treat propionic acidemia
Pharmaceutical Business Review
Wed, 10/23/19 - 09:29 am
Moderna Therapeutics
mRNA-3927
propionic acidemia
fast track
FDA